6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

April 24, 2017

 

 

KONINKLIJKE PHILIPS N.V.

(Exact name of registrant as specified in its charter)

 

 

Royal Philips

(Translation of registrant’s name into English)

The Netherlands

(Jurisdiction of incorporation or organization)

Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

Name and address of person authorized to receive notices

and communications from the Securities and Exchange Commission:

M.J. van Ginneken

Koninklijke Philips N.V.

Amstelplein 2

1096 BC Amsterdam – The Netherlands

 

 

 


This report comprises a copy of the following press release:

“Philips’ First Quarter Results 2017”, dated April 24, 2017.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 24th of April, 2017.

 

KONINKLIJKE PHILIPS N.V.
/s/ M.J. van Ginneken
(General Secretary)


LOGO

Philips reports sales of EUR 5.7 billion in Q1, with the HealthTech portfolio growing at 3% on a comparable basis; net income improved to EUR 259 million, driven by an 18% increase in Adjusted EBITA to EUR 442 million

Amsterdam, April 24, 2017

First-quarter highlights

 

  Sales increased to EUR 5.7 billion, with comparable sales growth of 3% in the HealthTech portfolio and 2% for the Group

 

  Net income amounted to EUR 259 million, compared to EUR 37 million in Q1 2016

 

  Income from operations (EBIT) amounted to EUR 348 million, compared to EUR 199 million in Q1 2016

 

  EBITA improved to EUR 437 million, or 7.6% of sales, compared to EUR 290 million, or 5.3% of sales, in Q1 2016

 

  Adjusted EBITA improved to EUR 442 million, or 7.7% of sales, compared to EUR 374 million, or 6.8% of sales, in Q1 2016

 

  Operating cash flow totaled EUR 343 million, compared to EUR 10 million in Q1 2016; free cash flow of EUR 295 million, compared to an outflow of EUR 177 million in Q1 2016

Frans van Houten, CEO:

“We had a solid start to the year, with 2% Group comparable sales growth and a 90-basis-point improvement in the Adjusted EBITA margin. Despite continued volatility in the markets in which we operate, our HealthTech portfolio grew 3% and achieved further operational improvements, resulting in an 80-basis-point increase in the Adjusted EBITA margin.

Our Diagnosis & Treatment businesses and our Personal Health businesses delivered strong margin improvements, while our Connected Care & Health Informatics businesses reflected the unevenness of sales from large hospital informatics deals.

Comparable order intake growth was 2%, driven by mid-single-digit growth in the Diagnosis & Treatment businesses.

During what was a very active quarter, in line with our strategic plan we decreased our shareholding in Philips Lighting to 55%. We continued to strengthen our position as a leader in health technology by launching several breakthrough innovations, forging strategic partnerships and winning various integrated solutions deals. The recent STOXX Europe 600 Index reclassification of Philips’ shares to ‘Health Care’ from ‘Industrial Goods & Services’ acknowledges our transformation into a health technology company.

As we execute our strategy, we will further improve our underlying performance and target to deliver 4-6% comparable sales growth and an improvement in Adjusted EBITA margin of around 100 basis points per year. Our outlook for 2017 remains unchanged as we expect further operational improvements and comparable sales growth in the year to be back-end loaded.”

HealthTech

In the first quarter, the Personal Health businesses increased sales by 5% on a comparable basis, with growth across the portfolio as Health & Wellness and Sleep & Respiratory Care recorded high-single-digit growth; the Adjusted EBITA margin improved by 150 basis points. The Diagnosis & Treatment businesses posted comparable sales growth of 2%, and the Adjusted EBITA margin improved by 190 basis points, driven by Diagnostic Imaging. In the Connected Care & Health Informatics businesses, comparable sales increased 1%, while the Adjusted EBITA margin was 30 basis points lower than in the same period last year, mainly reflecting lower growth and higher channel investments.


The continued focus and investments in R&D led to a number of breakthrough innovations and strategic collaborations:

 

  Philips reinforced its leadership in image-guided therapy solutions with the global launch of Philips Azurion, the next-generation image-guided therapy platform that enables clinicians to perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care.

 

  Philips Volcano continued its strong performance as the business reached an important milestone with the results of two large clinical trials demonstrating the benefits of Philips’ Instant Wave-Free Ratio (iFR) technology compared to Fractional Flow Reserve (FFR), the current standard, removing a critical barrier for the use and adoption of iFR to decide, guide and confirm appropriate therapies.

 

  B. Braun and Philips entered into a strategic alliance to innovate and accelerate growth in ultrasound-guided regional anesthesia and vascular access. The alliance launched Xperius, a new co-branded mobile ultrasound system specifically designed as the platform to support current and future integrated solutions in this fast-growing market.

 

  Building on its strategy to deliver relevant solutions and business models, Philips signed an agreement to acquire Australian Pharmacy Sleep Services (APSS), a pioneer in pharmacy sleep testing. APSS will complement Philips’ sleep and respiratory care portfolio and will help to accelerate the business’s home sleep testing offering through the pharmacy channel in Australia.

 

  At the International Dental Show in Germany, the world’s leading trade fair for the dental sector, Philips revealed the Philips Sonicare DiamondClean Smart toothbrush and Philips Sonicare Breath care system with breath analyzer, an all-in-one connected oral care platform. Philips also presented the results of a new clinical study demonstrating the effectiveness of Philips Sonicare power toothbrushes and Philips AirFloss Ultra.

 

  Demonstrating the success of telehealth technologies, Emory Healthcare (US) achieved savings of USD 4.6 million over a period of 15 months by using Philips’ eICU platform. Similarly, with the help of Philips’ Intensive Ambulatory Care program, Banner Health (US) reduced hospitalizations for chronically ill patients with multiple conditions by nearly 50%, reducing overall cost of care by more than one third.

 

  Expanding its health informatics portfolio, Philips launched its IntelliSpace Enterprise Edition, an industry-first managed service solution for hospital-wide clinical informatics and data management. The high-performance, secure and scalable health informatics platform enables health systems to manage the growth and cost of their clinical enterprise with a pay-per-use model.

 

  Further strengthening its portfolio of imaging solutions, Philips received FDA 510(k) clearance for its ElastQ ultrasound imaging technology for non-invasive assessment of liver conditions. Philips also launched Access CT, a new CT system designed for healthcare organizations seeking to establish or enhance CT imaging capabilities at affordable cost.

Cost savings

In the first quarter, procurement savings amounted to EUR 41 million. Other productivity programs resulted in savings of EUR 54 million.

Philips Lighting

In the first quarter, the Adjusted EBITA margin improved by 130 basis points to 8.5% of sales, while comparable sales were flat, and free cash flow amounted to EUR 2 million. Full details about the financial performance of Philips Lighting in the first quarter were published on April 21, 2017. The related report can be accessed here.

On February 8, 2017, Philips sold 26 million shares in Philips Lighting, of which 3.5 million shares were acquired by Philips Lighting (and will be cancelled). Philips’ shareholding in Philips Lighting decreased to 55.18% of Philips Lighting’s issued and outstanding share capital, down from 71.225% prior to the transaction. Philips continues to consolidate the financial results of Philips Lighting and maintains its aim of fully selling down over the coming years.

Philips Group other

As previously reported, Philips continues to be in discussions on a civil matter with the US Department of Justice representing the FDA, arising from past inspections by the FDA in and prior to 2015, focusing primarily on the external defibrillator business in the US.

Financing

On January 20, 2017, Philips completed the redemption of the outstanding 5.750% Notes due 2018 with an aggregate principal amount of USD 1.250 billion. The transaction resulted in a cash outflow in the first quarter of 2017 of EUR 1.247 billion excluding accrued interest. The transaction contributed to Philips’ plan to reduce its annual interest expenses by approximately EUR 100 million.

Conference call and audio webcast

Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results. A live audio webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here.


Philips Group performance

Key data

in millions of EUR unless otherwise stated

 

     Q1
2016
    Q1
2017
 

Sales

     5,517       5,724  

Nominal sales growth

     3     4

Comparable sales growth*

     3     2

Income from operations (EBIT)

     199       348  

as a % of sales

     3.6     6.1

EBITA*

     290       437  

as a % of sales

     5.3     7.6

Adjusted EBITA*

     374       442  

as a % of sales

     6.8     7.7

Financial expenses, net

     (114     (61

Investments in associates

     3       (1

Income taxes

     (75     (91

Income from continuing operations

     13       195  

Discontinued operations

     24       64  

Net income

     37       259  

Net income attributable to shareholders per common share (in EUR) - diluted

     0.03       0.25  

Sales per geographic cluster

in millions of EUR unless otherwise stated

 

    Q1     Q1     % change  
    2016     2017     nominal     comparable*  

Western Europe

    1,334       1,372       3     5

NorthAmerica

    1,937       1,958       1     (2 )% 

Other mature geographies

    459       474       3     (3 )% 
 

 

 

   

 

 

   

 

 

   

 

 

 

Total mature geographies

    3,730       3,804       2     0

Growth geographies

    1,787       1,920       7     6
 

 

 

   

 

 

   

 

 

   

 

 

 

Philips Group

    5,517       5,724       4     2
  Sales increased by 4% on a nominal basis. Excluding currency impact and consolidation changes, the 2% comparable sales growth was driven by 3% growth in the HealthTech portfolio.

 

  Comparable order intake* showed 2% growth, driven by mid- single-digit growth in the Diagnosis & Treatment businesses and a low-single-digit decline in the Connected Care & Health Informatics businesses.

 

  EBITA improved by EUR 147 million and the margin improved by 230 basis points compared to Q1 2016.

 

  Adjusted EBITA improved by EUR 68 million and the margin improved by 90 basis points compared to Q1 2016. The improvement was mainly attributable to higher volume, procurement savings and overhead cost reductions.

 

  Restructuring and acquisition-related charges amounted to EUR 34 million, compared to EUR 32 million in Q1 2016. EBITA also included EUR 12 million of charges related to the separation of the Lighting business, EUR 17 million of charges related to quality and regulatory actions, and a EUR 59 million net gain from the sale of real estate assets. EBITA in Q1 2016 included EUR 52 million of charges related to the separation of the Lighting business.

 

  Net financial expenses decreased by EUR 53 million year-on-year, mainly due to lower net interest expenses and the fair market value adjustment in Q1 2016 of Philips’ stake in Corindus Vascular Robotics.

 

  Income tax expense increased by EUR 16 million mainly due to higher income; Q1 2016 included tax charges resulting from activities related to the separation of the Lighting business.

 

  Net income from discontinued operations increased by EUR 40 million year-on-year, mainly due to improved operational performance in the combined Lumileds and Automotive businesses.

 

  Net income increased by EUR 222 million compared to Q1 2016, driven by improved income from operations and lower financial charges.

 

  Sales in mature geographies increased by 2% on a nominal basis. Excluding currency impact and consolidation changes, comparable sales were flat year-on-year and reflected mid- single-digit growth in Western Europe, offset by a low-single- digit decline in North America (due to Lighting) and other mature geographies. In growth geographies, sales increased by 7% on a nominal basis. Excluding currency impact and consolidation changes, the 6% growth on a comparable basis was largely driven by high-single-digit growth in Latin America and mid-single-digit growth in China and India.

 

  Comparable order intake* in mature geographies showed low- single-digit growth, reflecting double-digit growth in Western Europe and low-single-digit growth in North America and other mature geographies. In growth geographies, comparable order intake* was flat year-on-year, reflecting double-digit growth in China, offset by a double-digit decline in Latin America.
 

 

* Non-GAAP financial measure. Refer to Reconciliation of non-GAAP information, of this document.

 

LOGO   Quarterly report Q1 2017    3


 

Cash balance

 

in millions of EUR

 

    
     Q1
2016
    Q1
2017
 

Beginning cash balance

     1,766       2,334  

Free cash flow*

     (177     295  

Net cash flows from operating activities

     10       343  

Net capital expenditures

     (187     (48

Other cash flows from investing activities

     (97     (104

Treasury shares transactions

     (157     (57

Changes in debt

     75       (268

Sale of shares of Philips Lighting, net

       523  

Other cash flow items

     (40     (28

Net cash flows from discontinued operations

     15       36  
  

 

 

   

 

 

 

Ending cash balance

     1,385       2,731  

 

*  Non-GAAP financial measure. Refer to Reconciliation of non-GAAP information, of this document.
  Net cash flows from operating activities increased by EUR 333 million, mainly due to improvements in income from operations and the outflow of EUR 172 million in Q1 2016 related to pension liability de-risking. This was partly offset by a EUR 64 million premium payment related to the bond redemption completed on January 20, 2017.

 

  Net capital expenditures decreased by EUR 139 million, mainly due to proceeds from the sale of real estate assets.

 

  The change in debt reflects a new borrowing of EUR 949 million and a EUR 1,184 million cash outflow related to the bond redemption completed on January 20, 2017.

 

  The cash balance includes EUR 523 million net cash proceeds from the sale of a stake in Philips Lighting N.V.

 

 

 

4    Quarterly report Q1 2017    LOGO


Performance per segment

Personal Health businesses

Key data

in millions of EUR unless otherwise stated

 

     Q1
2016
    Q1
2017
 

Sales

     1,610       1,719  

Sales growth

    

Nominal sales growth

     6     7

Comparable sales growth*

     6     5

Income from operations (EBIT)

     190       231  

as a % of sales

     11.8     13.4

EBITA*

     225       266  

as a % of sales

     14.0     15.5

Adjusted EBITA*

     227       268  

as a % of sales

     14.1     15.6

Diagnosis & Treatment businesses

Key data

in millions of EUR unless otherwise stated

 

     Q1
2016
    Q1
2017
 

Sales

     1,419       1,491  

Sales growth

    

Nominal sales growth

     9     5

Comparable sales growth*

     5     2

Income from operations (EBIT)

     10       43  

as a % of sales

     0.7     2.9

EBITA*

     23       52  

as a % of sales

     1.6     3.5

Adjusted EBITA*

     32       63  

as a % of sales

     2.3     4.2
  Sales increased by 7% on a nominal basis. Excluding currency impact and consolidation changes, the 5% comparable sales growth was driven by high-single-digit growth in Sleep & Respiratory Care and Health & Wellness and mid-single-digit growth in Domestic Appliances.

 

  Comparable sales in growth geographies showed high-single- digit growth, reflecting double-digit growth in Middle East & Turkey, Latin America and Central & Eastern Europe and low-single-digit growth in China. Mature geographies recorded low-single-digit growth, reflecting mid-single-digit growth in Western Europe and North America and a mid-single-digit decline in other mature geographies.

 

  EBITA increased by EUR 41 million and the margin improved by 150 basis points compared to Q1 2016.

 

  Adjusted EBITA increased by EUR 41 million and the margin improved by 150 basis points compared to Q1 2016. The increase was attributable to operational leverage from growth.

 

  Restructuring and acquisition-related charges amounted to EUR 2 million and were in line with Q1 2016. In Q2 2017, restructuring and acquisition-related charges are expected to total approximately EUR 5 million.

 

  Sales increased by 5% on a nominal basis. Excluding currency impact, the 2% comparable sales growth reflected low-single-digit growth in Diagnostic Imaging, Ultrasound and Image-Guided Therapy.

 

  Comparable sales in growth geographies showed mid-single-digit growth, largely driven by double-digit growth in China and Latin America, partly offset by a double-digit decline in Central & Eastern Europe and a mid-single-digit decline in Middle East & Turkey. Mature geographies recorded low-single-digit growth, reflecting mid-single-digit growth in Western Europe, low-single-digit growth in other mature geographies and flat year-on-year comparable sales in North America.

 

  EBITA increased by EUR 29 million and the margin improved by 190 basis points compared to Q1 2016.

 

  Adjusted EBITA increased by EUR 31 million and the margin improved by 190 basis points year-on-year, mainly due to operational improvements and positive currency impact.

 

  Restructuring and acquisition-related charges were EUR 11 million, compared to EUR 9 million in Q1 2016. In Q2 2017, restructuring and acquisition-related charges are expected to total approximately EUR 40 million.
 

 

*  Non-GAAP financial measure. Refer to Reconciliation of non-GAAP information, of this document.

 

LOGO   Quarterly report Q1 2017    5


Connected Care & Health Informatics businesses

Key data

in millions of EUR unless otherwise stated

 

     Q1     Q1  
     2016     2017  

Sales

     694       732  

Sales growth

    

Nominal sales growth

     11     5

Comparable sales growth*

     9     1

Income from operations (EBIT)

     11       (12

as a % of sales

     1.6     (1.6 )% 

EBITA*

     23       0  

as a % of sales

     3.3     0.0

Adjusted EBITA*

     27       26  

as a % of sales

     3.9     3.6

HealthTech Other

Key data

in millions of EUR

 

     Q1
2016
    Q1
2017
 

Sales

     103       92  

Income from operations (EBIT)

     (9     12  

EBITA*

     (7     18  

Adjusted EBITA*

     (9     (38

IP Royalties

     57       50  

Innovation1)

     (44     (54

Central costs

     (21     (32

Other

     (1     (2

 

1)  Innovation includes Emerging Businesses

Lighting

Key data

in millions of EUR unless otherwise stated1)

 

     Q1
2016
    Q1
2017
 

Sales

     1,691       1,689  

Sales growth

    

Nominal sales growth

     (2 )%      0

Comparable sales growth*

     (2 )%      0

Income from operations (EBIT)

     73       105  

as a % of sales

     4.3     6.2

EBITA*

     102       133  

as a % of sales

     6.0     7.9

Adjusted EBITA*

     121       144  

as a % of sales

     7.2     8.5

 

1)  The Lighting segment results differ from the stand-alone Philips Lighting reporting mainly due to the exclusion of intercompany sales and the reporting within Legacy Items of Philips Lighting separation costs incurred.
  Sales increased by 5% on a nominal basis. Excluding currency impact and consolidation changes, the 1% comparable sales growth was driven by low-single-digit growth in Patient Care & Monitoring Solutions, partly offset by a low-single-digit decline in Healthcare Informatics, Solutions & Services.

 

  Comparable sales in growth geographies were in line with Q1 2016, reflecting double-digit growth in China, offset by a double-digit decline in India and Middle East & Turkey. Mature geographies posted low-single-digit growth, driven by high-single-digit growth in Western Europe and low-single-digit growth in North America, partly offset by a mid-single-digit decline in other mature geographies.

 

  EBITA decreased by EUR 23 million and the margin declined by 330 basis points compared to Q1 2016.

 

  The Adjusted EBITA margin decreased by 30 basis points year- on-year, mainly reflecting lower growth and higher channel investments.

 

  Restructuring and acquisition-related charges amounted to EUR 8 million, compared to EUR 4 million in Q1 2016. EBITA also included EUR 17 million of charges related to quality and regulatory actions. Restructuring and acquisition-related charges are expected to total approximately EUR 10 million in Q2 2017.

 

  Sales reflected EUR 14 million lower royalty income due to the foreseen expiration of licenses.

 

  EBITA increased by EUR 25 million year-on-year.

 

  The Adjusted EBITA decline was mainly attributable to lower royalty income, phasing of costs in Innovation and Central costs, as well as investments in rationalizing the IT landscape.

 

  Restructuring and acquisition-related charges amounted to EUR 3 million. EBITA included a EUR 59 million gain on the sale of real estate assets. EBITA in Q1 2016 included a EUR 2 million net release of restructuring charges. In Q2 2017, restructuring and acquisition-related charges are expected to total approximately EUR 5 million.

 

  Sales were flat year-on-year on both a nominal and comparable basis, reflecting double-digit growth in LED and Home, low-single-digit growth in Professional and a double- digit decline in Lamps, in line with the industry trend.

 

  Total LED lighting sales grew 19% and now represent 61% of total Lighting sales.

 

  EBITA increased by EUR 31 million and the margin improved by 190 basis points compared to Q1 2016.

 

  Adjusted EBITA continued to improve year-on-year. The EUR 23 million increase was largely driven by procurement savings and currency impact, partly offset by price erosion.

 

  Restructuring and acquisition-related charges were EUR 10 million, compared to EUR 19 million in Q1 2016. For information regarding the restructuring and acquisition-related charges guidance, please refer to the Philips Lighting Q1 2017 press release.
 

 

*  Non-GAAP financial measure. Refer to Reconciliation of non-GAAP information, of this document.

 

6    Quarterly report Q1 2017    LOGO


Legacy Items

Income from operations (EBIT)

in millions of EUR

 

     Q1
2016
    Q1
2017
 

Separation costs

     (52     (12

Other

     (24     (19
  

 

 

   

 

 

 

Income from operations (EBIT)

     (76     (31

Discontinued operations

Net income of discontinued operations

in millions of EUR

 

     Q1
2016
    Q1
2017
 

The combined Lumileds and Automotive businesses

     32       65  

Other

     (8     (1
  

 

 

   

 

 

 

Net income of discontinued operations

     24       64  

 

    Income from operations (EBIT) mainly included EUR 12 million of charges related to the separation of the Lighting business, EUR 9 million of stranded costs related to the combined Lumileds and Automotive businesses, and EUR 3 million related to movements in environmental provisions.

 

    Charges related to the separation of the Lighting business are expected to total approximately EUR 15 million in Q2 2017.

 

 

    Net income of the combined businesses of Lumileds and Automotive increased by EUR 33 million, mainly due to higher sales and improvements in gross margins.

 

    Philips has signed an agreement to sell an 80.1% interest in the combined Lumileds and Automotive businesses to certain funds managed by affiliates of Apollo Global Management, LLC. Philips will retain the remaining 19.9% interest. The transaction is expected to be completed in Q2 2017, subject to customary closing conditions, including the relevant regulatory approvals.
 

 

LOGO   Quarterly report Q1 2017    7


EBITA* and Adjusted EBITA* - HealthTech portfolio segments

Personal Health businesses

 

EBITA*

in millions of EUR unless otherwise stated

 

LOGO

Adjusted EBITA*

in millions of EUR unless otherwise stated

 

LOGO

 

 

Diagnosis & Treatment businesses

EBITA*

in millions of EUR unless otherwise stated

 

LOGO

Adjusted EBITA*

in millions of EUR unless otherwise stated

 

LOGO

 

 

Connected Care & Health Informatics businesses

EBITA*

in millions of EUR unless otherwise stated

 

LOGO

Adjusted EBITA*

in millions of EUR unless otherwise stated

 

LOGO

 

 

*  Non-GAAP financial measure. Refer to Reconciliation of non-GAAP information, of this document.

 

8    Quarterly report Q1 2017    LOGO


Forward-looking statements and other important information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include but are not limited to: domestic and global economic and business conditions; developments within the euro zone; the successful implementation of Philips’ strategy and the ability to realize the benefits of this strategy; the ability to develop and market new products; changes in legislation; legal claims; changes in exchange and interest rates; changes in tax rates; pension costs and actuarial assumptions; raw materials and employee costs; the ability to identify and complete successful acquisitions, and to integrate those acquisitions into the business; the ability to successfully exit certain businesses or restructure the operations; the rate of technological changes; political, economic and other developments in countries where Philips operates; industry consolidation and competition; and the state of international capital markets as they may affect the timing and nature of the dispositions by Philips of its interests in Philips Lighting and the combined Lumileds and Automotive businesses. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see the Risk management chapter included in the Annual Report 2016.

Third-party market share data

Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.

Use of non-GAAP information

In presenting and discussing the Philips Group financial position, operating results and cash flows, management uses certain non- GAAP financial measures. These non-GAAP financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used in conjunction with the most directly comparable IFRS measures. Non-GAAP financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-GAAP measures

to the most directly comparable IFRS measures is contained in this document. Further information on non-GAAP measures can be found in the Annual Report 2016.

Use of fair-value measurements

In presenting the Philips Group financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2016. Independent valuations may have been obtained to support management’s determination of fair values.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2016, unless otherwise stated.

As part of the financial reporting improvement process, the presentation of the line item Investments in associates was moved into the subtotal Income before taxes in the Condensed consolidated statements of income. This change did not impact the results of operations or financial position.

In addition, we have simplified our Q1 and Q3 reporting by excluding the cash flow statement, the statement of changes in equity and certain other tables in the detailed financial information section not required to be disclosed. In our semi- annual and annual reporting we will continue to present these statements and tables. Summary cash flow information is provided in the Philips performance section of this document.

Prior-period financial statements have been restated to reflect a reclassification of Net defined-benefit post-employment plan obligations to Long-term provisions in accordance with the accounting policies as stated in the Annual Report 2016.

Accordingly, Q1 2016 has been restated and presented for the first time in this press release.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

 

 

LOGO   Quarterly report Q1 2017    9


Condensed consolidated statements of income

Condensed consolidated statements of income

in millions of EUR unless otherwise stated

 

     Q1  
     2016     2017  

Sales

     5,517       5,724  

Cost of sales

     (3,251     (3,280
  

 

 

   

 

 

 

Gross margin

     2,266       2,444  

Selling expenses

     (1,418     (1,466

General and administrative expenses

     (189     (199

Research and development expenses

     (470     (518

Impairment of goodwill

     (2     —    

Other business income

     21       91  

Other business expenses

     (9     (5
  

 

 

   

 

 

 

Income from operations

     199       348  

Financial income

     27       25  

Financial expenses

     (141     (86

Investments in associates

     3       (1
  

 

 

   

 

 

 

Income before taxes

     88       286  

Income taxes

     (75     (91
  

 

 

   

 

 

 

Income from continuing operations

     13       195  

Discontinued operations - net of income taxes

     24       64  
  

 

 

   

 

 

 

Net income

     37       259  

Attribution of net income for the period

    

Net income attributable to Koninklijke Philips N.V. shareholders

     32       232  

Net income attributable to Non-controlling interests

     5       27  

Earnings per common share attributable to shareholders

    

Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands):

    

- basic

     913,929       921,917  

- diluted

     924,706       937,102  

Net income attributable to shareholders per common share in EUR:

    

- basic

     0.04       0.25  

- diluted

     0.03       0.25  

Amounts may not add up due to rounding.

 

10    Quarterly report Q1 2017    LOGO


Condensed consolidated balance sheets

Condensed consolidated balance sheets

in millions of EUR

 

    

March 31,

2016

   

December 31,

2016

    

March 31,

2017

 

Non-current assets:

       

Property, plant and equipment

     2,218       2,155        2,122  

Goodwill

     8,265       8,898        8,751  

Intangible assets excluding goodwill

     3,526       3,552        3,441  

Non-current receivables

     166       155        167  

Investments in associates

     205       190        189  

Other non-current financial assets

     436       335        373  

Non-current derivative financial assets

     45       59        56  

Deferred tax assets

     2,689       2,792        2,766  

Other non-current assets

     70       92        92  

Total non-current assets

     17,620       18,228        17,956  

Current assets:

       

Inventories

     3,601       3,392        3,629  

Other current financial assets

     12       101        97  

Other current assets

     523       486        541  

Current derivative financial assets

     87       101        54  

Income tax receivable

     120       154        157  

Receivables

     4,597       5,327        4,660  

Assets classified as held for sale

     1,812       2,180        2,038  

Cash and cash equivalents

     1,385       2,334        2,731  

Total current assets

     12,137       14,075        13,908  

Total assets

     29,757       32,303        31,864  

Equity

       

Shareholders’ equity

     11,279       12,601        12,698  

Non-controlling interests

     130       907        1,332 2) 

Group equity

     11,409       13,508        14,030  

Non-current liabilities:

       

Long-term debt

     3,984       4,021        3,969  

Non-current derivative financial liabilities

     518       590        433  

Long-term provisions

     3,234 1)      2,926        2,888  

Deferred tax liabilities

     129       66        68  

Other non-current liabilities

     717 1)      719        675  

Total non-current liabilities

     8,582       8,322        8,032  

Current liabilities:

       

Short-term debt

     1,705       1,585        1,375  

Current derivative financial liabilities

     268       283        269  

Income tax payable

     153       146        192  

Accounts payable

     2,434       2,848        2,900  

Accrued liabilities

     2,678 1)      3,034        2,629  

Short-term provisions

     730 1)      680        632  

Liabilities directly associated with assets held for sale

     430       525        490  

Other current liabilities

     1,368       1,372        1,315  
  

 

 

   

 

 

    

 

 

 

Total current liabilities

     9,766       10,473        9,802  
  

 

 

   

 

 

    

 

 

 

Total liabilities and group equity

     29,757       32,303        31,864  

 

1)  Adjusted to reflect a reclassification of net defined-benefit obligations into long-term provisions.
2)  The increase in Non-controlling interests is due to the sale of 26 million shares of Philips Lighting in February 2017 which increased the percentage of Non-controlling interests from 28.775% to 44.820%.

Amounts may not add up due to rounding.

 

LOGO   Quarterly report Q1 2017    11


Segment information

Sales and income from operations

in millions of EUR unless otherwise stated

 

       Q1 2016      Q1 2017  
       sales        Income from operations      sales        Income from operations  
                      as a % of sales                     as a % of sales  

Personal Health

       1,610          190       11.8      1,719          231       13.4

Diagnosis & Treatment

       1,419          10       0.7      1,491          43       2.9

Connected Care & Health Informatics

       694          11       1.6      732          (12     (1.6 )% 

HealthTech Other

       103          (9        92          12    

Lighting

       1,691          73       4.3      1,689          105       6.2

Legacy Items

            (76             (31  
    

 

 

      

 

 

   

 

 

    

 

 

      

 

 

   

 

 

 

Philips Group

       5,517          199       3.6      5,724          348       6.1

 

12    Quarterly report Q1 2017    LOGO


Reconciliation of non-GAAP information

Certain non-GAAP financial measures are presented when discussing the Philips Group’s performance:

 

  Comparable sales growth

 

  EBIT

 

  EBITA

 

  Adjusted EBITA

 

  Free cash flow

 

  Net debt : group equity ratio

 

  Order intake

The term EBIT has the same meaning as Income from operations.

Adjusted EBITA is defined as Income from operations (EBIT) excluding amortization of intangible assets (excluding software and development expenses), impairment of goodwill and other intangible assets, restructuring charges, acquisition-related costs and other significant items.

Free cash flow is defined as Net cash from operating activities minus net capital expenditures. Net capital expenditures are comprised of the purchase of intangible assets, expenditures on development assets, capital expenditures on property, plant and equipment and proceeds from disposal of property, plant and equipment.

Order intake is reported for equipment and software and is defined under our policy as the total contractually committed amount to be delivered within a specified timeframe. Order intake does not derive from the financial statements and thus a quantitative reconciliation is not provided. Order intake is calculated on a comparable basis, which excludes the effects of currency movements and changes in consolidation.

For the definitions of the remaining non-GAAP financial measures listed above, refer to the Annual Report 2016. In the following tables, reconciliations to the most directly comparable IFRS measures are presented.

Sales growth composition

in %

 

     Q1 2017  
     nominal
growth
    consolidation
changes
    currency
effects
    comparable
growth
 

2017 versus 2016

        

Personal Health

     6.8     0.5     (2.1 )%      5.2

Diagnosis & Treatment

     5.1     0.0     (3.0 )%      2.1

Connected Care & Health Informatics

     5.5     (0.7 )%      (3.3 )%      1.5

HealthTech Other

     (10.7 )%      0.0     (0.1 )%      (10.8 )% 

Lighting1)

     (0.1 )%      0.9     (1.2 )%      (0.4 )% 
  

 

 

   

 

 

   

 

 

   

 

 

 

Philips Group

     3.8     0.3     (2.1 )%      2.0

 

1)  The Lighting segment results differ from the stand-alone Philips Lighting reporting mainly due to the exclusion of intercompany sales

 

LOGO   Quarterly report Q1 2017    13


Net income to Adjusted EBITA

In millions of EUR unless otherwise stated

 

     Philips Group     Personal
Health
     Diagnosis &
Treatment
     Connected
Care & Health
Informatics
    HealthTech
Other
    Lighting1)      Legacy Items  

Q1 2017

                 

Net Income

     259                 

Discontinued operations, net of income taxes

     64                 

Income taxes

     (91               

Investments in associates

     (1               

Financial expenses

     (86               

Financial income

     25                 
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Income from operations (EBIT)

     348       231        43        (12     12       105        (31

Amortization of acquired intangible assets

     90       35        9        12       6       28        —    
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

EBITA

     437       266        52        0       18       133        (31

Restructuring and aquisition-related charges

     34       2        11        8       3       10     

Other items

     (30           17       (59     1        11  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Adjusted EBITA

     442       268        63        26       (38     144        (20

Q1 2016

                 

Net Income

     37                 

Discontinued operations, net of income taxes

     24                 

Income taxes

     (75               

Investments in associates

     3                 

Financial expenses

     (141               

Financial income

     27                 
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Income from operations (EBIT)

     199       190        10        11       (9     73        (76

Amortization of acquired intangible assets

     89       35        13        12       2       27        —    

Impairment of goodwill

     2       —          —          —         —         2        —    
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

EBITA

     290       225        23        23       (7     102        (76

Restructuring and aquisition-related charges

     32       2        9        4       (2     19     

Other Items

     52                    52  
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

    

 

 

 

Adjusted EBITA

     374       227        32        27       (9     121        (24

 

1)  The Lighting segment results differ from the stand-alone Philips Lighting reporting mainly due to the reporting within Legacy Items of Philips Lighting separation costs incurred.

Composition of net debt and group equity

in millions of EUR unless otherwise stated

 

     March 31,
2016
    December 31,
2016
    March 31,
2017
 

Long-term debt

     3,984       4,021       3,969  

Short-term debt

     1,705       1,585       1,375  
  

 

 

   

 

 

   

 

 

 

Total debt

     5,689       5,606       5,344  

Cash and cash equivalents

     1,385       2,334       2,731  
  

 

 

   

 

 

   

 

 

 

Net debt1)

     4,304       3,272       2,613  

Shareholders’ equity

     11,279       12,601       12,698  

Non-controlling interests

     130       907       1,332  
  

 

 

   

 

 

   

 

 

 

Group equity

     11,409       13,508       14,030  

Net debt and group equity

     15,713       16,780       16,643  

Net debt divided by net debt and group equity (in %)

     27     19     16

Group equity divided by net debt and group equity (in %)

     73     81     84

Net debt : group equity ratio

     27:73       19:81       16:84  

 

1)  Total debt less cash and cash equivalents

 

14    Quarterly report Q1 2017    LOGO


Philips statistics

in millions of EUR unless otherwise stated

 

     2016     2017  
     Q1     Q2     Q3     Q4     Q1       Q2          Q3          Q4    

Sales

     5,517       5,861       5,898       7,240       5,724          

Comparable sales growth*

     3     3     2     3     2        

Gross margin

     2,266       2,538       2,603       3,205       2,444          

as a % of sales

     41.1     43.3     44.1     44.3     42.7        

Selling expenses

     (1,418     (1,427     (1,411     (1,632     (1,466        

as a % of sales

     (25.7 )%      (24.3 )%      (23.9 )%      (22.5 )%      (25.6 )%         

G&A expenses

     (189     (234     (203     (219     (199        

as a % of sales

     (3.4 )%      (4.0 )%      (3.4 )%      (3.0 )%      (3.5 )%         

R&D expenses

     (470     (501     (514     (536     (518        

as a % of sales

     (8.5 )%      (8.5 )%      (8.7 )%      (7.4 )%      (9.0 )%         

Income from operations (EBIT)

     199       376       481       826       348          

as a % of sales

     3.6     6.4     8.2     11.4     6.1        

EBITA*

     290       464       567       914       437          

as a % of sales

     5.3     7.9     9.6     12.6     7.6        

Net income

     37       431       383       640       259          

Net income attributable to shareholders

     32       420       370       626       232          

Net income - shareholders per common share in EUR - diluted

     0.03       0.46       0.40       0.67       0.25          

 

     2016     2017  
     January-
March
    January-
June
    January-
September
    January-
December
    January-
March
    January-
June
     January-
September
     January-
December
 

Sales

     5,517       11,378       17,276       24,516       5,724          

Comparable sales growth*

     3     3     3     3     2        

Gross margin

     2,266       4,804       7,407       10,612       2,444          

as a % of sales

     41.1     42.2     42.9     43.3     42.7        

Selling expenses

     (1,418     (2,845     (4,256     (5,888     (1,466        

as a % of sales

     (25.7 )%      (25.0 )%      (24.6 )%      (24.0 )%      (25.6 )%         

G&A expenses

     (189     (423     (626     (845     (199        

as a % of sales

     (3.4 )%      (3.7 )%      (3.6 )%      (3.4 )%      (3.5 )%         

R&D expenses

     (470     (971     (1,485     (2,021     (518        

as a % sales

     (8.5 )%      (8.5 )%      (8.6 )%      (8.2 )%      (9.0 )%         

Income from operations (EBIT)

     199       575       1,056       1,882       348          

as a % of sales

     3.6     5.1     6.1     7.7     6.1        

EBITA*

     290       754       1,321       2,235       437          

as a % of sales

     5.3     6.6     7.6     9.1     7.6        

Net income

     37       468       851       1,491       259          

Net income attributable to shareholders

     32       452       822       1,448       232          

Net income - shareholders per common share in EUR - diluted

     0.03       0.49       0.89       1.56       0.25          

Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands)

     913,011       927,316       924,271       922,437       920,276          

Shareholders’ equity per common share in EUR

     12.35       12.39       12.57       13.66       13.80          

Net debt : group equity ratio*

     27:73       24:76       24:76       19:81       16:84          

Total employees

     114,021       113,356       113,627       114,731       114,188          

of which discontinued operations

     8,913       9,158       9,531       9,508       9,381          

of which third-party workers

     12,250       11,604       11,822       12,774       12,779          

 

*  Non-GAAP financial measure. Refer to Reconciliation of non-GAAP information, of this document.

 

LOGO   Quarterly report Q1 2017    15


LOGO

http://www.philips.com/investorrelations

© 2017 Koninklijke Philips N.V. All rights reserved.